Meeting
2024 ASCO Genitourinary Cancers Symposium
Cost-effectiveness of triplet therapies in metastatic hormone-sensitive prostate cancer used in PEACE-1 and ARASENS.
Authors
Nataniel Hernan Lester-Coll
University of Vermont Larner College of Medicine, Burlington, VT
Nataniel Hernan Lester-Coll , David Joseph Benjamin , Hélène Ribault , Stéphanie Foulon , Karim Fizazi , Arash Rezazadeh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Other
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 222)
DOI
10.1200/JCO.2024.42.4_suppl.222
Abstract #
222
Poster Bd #
K10
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
A systematic review: Are the findings of indirect treatment comparisons (ITCs) in metastatic hormone-sensitive prostate cancer (mHSPC) consistent?
First Author: Neal D. Shore
Poster
2023 ASCO Genitourinary Cancers Symposium
Oncologists’ perspectives on metastatic hormone sensitive prostate cancer management.
First Author: Patrick Heckman
Poster
2021 Genitourinary Cancers Symposium
Real-world survival of men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with abiraterone acetate (Abi) or docetaxel (Doc) and comparison with clinical trial outcomes.
First Author: Daniel M. Geynisman
Poster
2018 ASCO Annual Meeting
Cost-effectiveness analysis of abiraterone acetate (AA) versus docetaxel (D) for the management of metastatic hormone naïve prostate cancer (mHNPC).
First Author: Chethan Ramamurthy